Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Mar 24;9(3):135.
doi: 10.3390/antibiotics9030135.

Bacteriophage Therapy: Developments and Directions

Mikeljon P Nikolich  1 , Andrey A Filippov  1
Affiliations
Review

Bacteriophage Therapy: Developments and Directions

Mikeljon P Nikolich et al. Antibiotics (Basel). .

Abstract

In an era of proliferating multidrug resistant bacterial infections that are exhausting the capacity of existing chemical antibiotics and in which the development of new antibiotics is significantly rarer, Western medicine must seek additional therapeutic options that can be employed to treat these infections. Among the potential antibacterial solutions are bacteriophage therapeutics, which possess very different properties from broad spectrum antibiotics that are currently the standard of care, and which can be used in combination with them and often provide synergies. In this review we summarize the state of the development of bacteriophage therapeutics and discuss potential paths to the implementation of phage therapies in contemporary medicine, focused on fixed phage cocktail therapeutics since these are likely to be the first bacteriophage products licensed for broad use in Western countries.

Keywords: antimicrobial; bacteriophage therapy; multidrug resistance; phage cocktail.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Sulakvelidze A., Alavidze Z., Morris J.G., Jr. Bacteriophage Therapy. Antimicrob. Agents Chemother. 2001;45:649–659. doi: 10.1128/AAC.45.3.649-659.2001. - DOI - PMC - PubMed
    1. Kutateladze M., Adamia R. Bacteriophages as Potential New Therapeutics to Replace or Supplement Antibiotics. Trends Biotechnol. 2010;28:591–595. doi: 10.1016/j.tibtech.2010.08.001. - DOI - PubMed
    1. Międzybrodzki R., Hoyle N., Zhvaniya F., Lusiak-Szelachowska M., Weber-Dabrowska B., Lobocka M., Borysowski J., Alavidze Z., Kutter E., Górski A., et al. Current Updates from the Long-standing Phage Research Centers in Georgia, Poland and Russia. In: Harper D., Abedon S., Burrowes B., editors. Bacteriophages. Springer; Cham, Switzerland: 2018. pp. 1–31.
    1. Antibiotic Resistance Threats in the United States. U.S. Department of Health and Human Services, CDC; Atlanta, GA, USA: 2019.
    1. Neu H.C. The Crisis in Antibiotic Resistance. Science. 1992;257:1064–1073. doi: 10.1126/science.257.5073.1064. - DOI - PubMed

LinkOut - more resources